{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:52:41Z","timestamp":1777949561292,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"DOI":"10.1186\/s12877-025-06660-8","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:32:40Z","timestamp":1774420360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tislelizumab-induced lichenoid drug eruption and cutaneous squamous cell carcinoma: a rare dermatologic immune-related adverse event"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"6660_CR1","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.2147\/DDDT.S267433","volume":"14","author":"L Ai","year":"2020","unstructured":"Ai L, et al. Research status and outlook of PD-1\/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625\u201349.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"6660_CR2","doi-asserted-by":"publisher","first-page":"e2021155","DOI":"10.5826\/dpc.1101a155","volume":"11","author":"Z Apalla","year":"2021","unstructured":"Apalla Z, et al. Cutaneous adverse events of immune checkpoint inhibitors: A literature review. Dermatol Pract Concept. 2021;11(1):e2021155.","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"6660_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/1759-7714.13275","volume":"11","author":"X Si","year":"2020","unstructured":"Si X, et al. Management of immune checkpoint inhibitor-related dermatologic adverse events. Thorac Cancer. 2020;11(2):488\u201392.","journal-title":"Thorac Cancer"},{"issue":"7","key":"6660_CR4","doi-asserted-by":"publisher","first-page":"6805","DOI":"10.3390\/curroncol30070498","volume":"30","author":"YS Teng","year":"2023","unstructured":"Teng YS, Yu S. Molecular mechanisms of cutaneous immune-Related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 2023;30(7):6805\u201319.","journal-title":"Curr Oncol"},{"issue":"4","key":"6660_CR5","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/curroncol29040234","volume":"29","author":"CH Chen","year":"2022","unstructured":"Chen CH, Yu HS, Yu S. Cutaneous adverse events associated with immune checkpoint inhibitors: A review Article. Curr Oncol. 2022;29(4):2871\u201386.","journal-title":"Curr Oncol"},{"issue":"6","key":"6660_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1684\/ejd.2022.4378","volume":"32","author":"C Eldani","year":"2022","unstructured":"Eldani C, et al. Successful Rechallenge for severe lichenoid drug reaction to pembrolizumab presenting as toxic epidermal necrolysis-like. Eur J Dermatol. 2022;32(6):805\u20137.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"6660_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.29021\/spdv.79.1.1288","volume":"79","author":"R Pimenta","year":"2021","unstructured":"Pimenta R, Costa-Rosa J, Cravo M, et al. Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma. J Port Soc Dermatol Venereol. 2021;79(1):11\u201320.","journal-title":"J Port Soc Dermatol Venereol"},{"key":"6660_CR8","doi-asserted-by":"crossref","unstructured":"McCormick BJ et al. Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab. BMJ Case Rep. 2023;16(6):e254692.","DOI":"10.1136\/bcr-2023-254692"},{"issue":"4","key":"6660_CR9","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00403-022-02468-3","volume":"315","author":"M Poole","year":"2023","unstructured":"Poole M, et al. To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma. Arch Dermatol Res. 2023;315(4):903\u201315.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"6660_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamadermatol.2024.0390","volume":"160","author":"P Aggarwal","year":"2024","unstructured":"Aggarwal P, et al. Keratoacanthoma and cutaneous squamous cell carcinoma with PD-1 and PD-L1 inhibitor use. JAMA Dermatol. 2024;160(5):573\u20135.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"6660_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/ijdd.ijdd_31_23","volume":"10","author":"KS Bhoite","year":"2024","unstructured":"Bhoite KS, Mahajan SA, et al. Lichenoid drug reactions: A retrospective clinicpidemiological, and histopathological study of 55 cases. Indian J Drugs Dermatol. 2024;10(1):26\u201335.","journal-title":"Indian J Drugs Dermatol."},{"issue":"7","key":"6660_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","volume":"5","author":"F Berner","year":"2019","unstructured":"Berner F, et al. Association of checkpoint Inhibitor-Induced toxic effects with shared cancer and tissue antigens in Non-Small cell lung cancer. JAMA Oncol. 2019;5(7):1043\u20137.","journal-title":"JAMA Oncol"},{"issue":"9","key":"6660_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00262-017-2015-x","volume":"66","author":"T Gambichler","year":"2017","unstructured":"Gambichler T, et al. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma. Cancer Immunol Immunother. 2017;66(9):1199\u2013204.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"6660_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, et al. Management of Immunotherapy-Related Toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"6660_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","volume":"153","author":"A Freites-Martinez","year":"2017","unstructured":"Freites-Martinez A, et al. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol. 2017;153(7):694\u20137.","journal-title":"JAMA Dermatol"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-025-06660-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06660-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-025-06660-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:44:49Z","timestamp":1777855489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12877-025-06660-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6660"],"URL":"https:\/\/doi.org\/10.1186\/s12877-025-06660-8","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Second Affiliated Hospital of Wannan Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}},{"value":"The patient forgranting us permission to publish this information and written Informed Consent for publication was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"624"}}